Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Allied Corp. (ALID)
Kelowna, BC, CA
Allied Corp. (ALID) specializes in the research, development, and production of cannabinoid health solutions, primarily operating in the United States. The company markets a diverse portfolio of natural health products derived from hemp under various brands. Its "Tactical Relief" line features items such as Liberty, a CBD tincture; Tactical Hydration, a CBD-infused electrolyte beverage; FIZZ Tablets designed for water bottles; Battle Balm, a CBD roll-on formulated for activity-related aches and pains; and Quick Hit, a CBD gummy. Similarly, the "Equilibrium Bio" brand encompasses Hydrosport CBD Drink, an electrolyte beverage fortified with sodium citrate; Hydrosport Tincture, a CBD tincture enhanced with specific terpene profiles; FIZZ Tablets for customizable drinks; Sport Rub, a CBD topical for post-activity muscle relief; and Quick Hit, a CBD gummy enriched with vitamin B12. Additionally, Allied Corp. distributes a specialized skincare line under its "MaXXa" brand. This collection features Skin Structure, a facial formula for enhancing skin radiance and youthfulness; Eye Recover, designed to protect delicate eye skin from free radicals and sun damage; Glossy Lip Recover, which moisturizes and nourishes lips; Skin Designer, stimulating cell regeneration and minimizing age spots; Vitamin Absolute, a hydrating facial oil; and Absolute Recover, a formulation for direct delivery of bioactive compounds to address inflammation, pain, and other skin ailments. Beyond its consumer product portfolio, Allied Corp. is also engaged in pharmaceutical development, with ALID 10 and ALID 11, experimental drug candidates, currently in Phase I clinical trials for the treatment of post-traumatic stress disorder (PTSD). Established in 2013, Allied Corp. maintains its corporate headquarters in Kelowna, Canada.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | 0.00% | 0.00% | 0.00% | -95.50% | 0.00% | -95.58% | -99.81% | -99.95% | -99.96% | -99.96% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-56.5% Q3'23: -97.9% (vs Q3'22)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+38.9% ★ Q3'23: -415.5% (vs Q3'22)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-11,617.6% Q3'23: +2,067.9% (vs Q3'22)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+0.0% Q3'23: -94,589.8% (vs Q3'22)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%— Q3'23: +758.5% (vs Q3'22)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+5.1% Q3'23: +20.4% (vs Q3'22)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×-0.88× Q3'23: -0.64× (vs Q3'22)
Owner Earnings
Ownership Overview
Ownership breakdown not available.
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Anthony Zelen | 9.79M | 14.00% | 9.79M | — | 9.79M | — | IN | Canada | 2019-10-03 | ↗ |
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-04-27 | Robinson James George | Director / 10% Owner | P-Purchase | A | Common Stock | 40,000 | 0.47 | 18.8K | 4,782,065 | — | ↗ |
| 2023-04-25 | Robinson James George | Director / 10% Owner | P-Purchase | A | Common Stock | 40,000 | 0.45 | 18.0K | 4,742,065 | — | ↗ |
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Michael Moses | Chief Executive Officer | 150.0K | male |
| Paul Bullock | Chief Operating Officer, Interim Chief Financial Officer & Director | 92.6K | male |
| James Smeeding | Vice President of Pharmaceuticals Development & Director | 60.0K | male |
| Mark Moses | Chief of Staff | — | male |
| Radka Milanova | Chief Scientific Director | — | — |
| Tim Levy | Head of Cultivation | — | male |
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ALID
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
